Arterial Remodeling Technologies (“ART”) Reports $2.9 Million Cash Infusion to Prepare Its Next-generation Bioresorbable Stent for First-in-Human Study  
4/4/2012 10:08:41 AM

PARIS--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) reported today that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at six months follow-up. In addition, acute safety data are promising: there have been more than 300 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.